Is Advanced Prostate Cancer Changing? The Evolution of Metastatic Castrate Resistant Prostate Cancer And The Need To Make Some Research Changes

Metastatic castration-resistant prostate cancer (mCRPC) is known as a cancer that more often than not metastasizes to the bone. Less often it moves to nonosseous sites (soft tissue sites like lymph nodes, liver and lung). The last few years has seen the development of new drugs that extend the survival of men. Because of these [...]

Lethal Advanced Prostate Cancer Has Inherently Heterogeneity And Can Spread From Other Metastatic Sites

We still have a lot to learn about how prostate cancer actually spreads, or metastasizes. Current theory holds that the primary tumor is probably most responsible for the development of distant metastases. In a new genomic analysis of tissue performed at the Johns Hopkins University using tissue from prostate cancer patients this paradigm has been [...]

Understanding Oligometastic Prostate Cancer & Our Ability to Successfully Treat It

It is the general consensus that prostate cancer when still confined to the prostate gland is gland curable, but when it has left the prostate gland and becoming metastatic it is no longer curable. But evidence now says there might be an intermediate stage where the cancer has spread outside the prostate gland but is [...]

Where Are The Prostate Cancer Mets Located?

Sometimes I have heard the question, Where can prostate cancer metastasis (met) be found? Usually, the question really means, how can my met in my spleen or liver (or what ever) come from my prostate cancer? In realty, prostate cancer tumors can develop anywhere in the human body! There was a study of human cadavers [...]

The effect of PSA doubling time (PSADT) and Gleason score on the PSA at the time of initial metastasis in men with biochemical recurrence after prostatectomy.

The researchers took a cohort of 430 men with a biochemical recurrence (PSA increase only) after failed prostatectomy. The men underwent observation until they experienced metastatic disease as determined by CT or bone scan. The researchers then evaluated the PSA at the time the men developed metastasis for those patients who developed metastatic disease. PSA [...]

Prostate Cancer SATURN Trial, a Phase 3 Trial in Men with Metastatic Prostate Cancer

A new phase 3, registration trial has been announced by OncoGenex Pharmaceuticals, Inc. of its investigational drug custirsen sodium (OGX-011/TV-1011). The trial, for men with metastatic castrate resistant prostate cancer (mCRPC) is referred to as the Prostate Cancer SATURN Trial. This randomized, controlled, trial will include approximately 50 cancer centers and is planned to enroll [...]

Early Hormone Therapy, Is It Good or Bad for Us?

I have just read a report from Mike Scott of a 64-year-old Croatian man who was recently diagnosed with advanced prostate cancer. His PSA was 21,380 ng/ml! Yes, I said a PSA of 21,380. Now, hold on to your seats for even more intriguing information. According to the report this man has never experienced any [...]

A Telephone Workshop on Metastatic Prostate Cancer

Cancer Care is conducting a telephone workshop on Metastatic Prostate Cancer on Tuesday, September 22, 2009 from 1:30 to 2:30 eastern time. Listening in on the workshop is free. Participants in the workshop will be: Susan Slovin MD, PhD, Associate Attending Physician, Genitourinary Oncology Service, Sidney Kimmel Center for the Treatment of Prostate & Urologic [...]

Maybe A Misnomer – Prostate Cancer Resistance to Androgen Deprivation Therapy

The use of ADT is the treatment of choice for advanced, metastatic prostate cancer as long as the cancer is responsive to the blockade. The theory goes that the suppression of circulating testosterone, which fuels prostate-cancer growth, whether by surgical castration (orchiectomy) or castration with testosterone-blocking drugs slows down the progression of the prostate cancer. [...]

Go to Top